Oragenics Inc. OGEN
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Oragenics Inc. (OGEN) is a healthcare company listed in the US with a market value of about $906903.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -1572%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 99% below the current price.
About Oragenics
Oragenics is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $939926 in 2014 to $37653 in 2023, a decline of about 30.1% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 3121% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $37653 | $131521 | $86987 | — | — | $0 | $0 | $0 |
| Net income | -$10M | -$11M | -$21M | -$14M | -$16M | -$26M | -$16M | -$10M | -$7M | -$7M |
| Free cash flow | — | — | — | -$15M | -$14M | — | -$13M | -$9M | — | -$7M |
| EPS (diluted) | $-2.28 | $-23.94 | $-137.70 | $-106.65 | $-2.10 | $-7.05 | $-5.55 | $-13.05 | $-20.55 | $-23.55 |
| Net margin | — | — | -54858.1% | -10864.0% | -18062.0% | — | — | — | — | — |
| ROIC | -108.5% | -7151.3% | -473.1% | -83.6% | -45.7% | -118.6% | -68.9% | -47.6% | -106.4% | -288.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Oragenics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 99% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Oragenics pay a dividend?
Not currently.
Is Oragenics a good stock to buy?
We do not give buy or sell advice. Oragenics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.